Wölfel B, Hartung K, Haak A, Kaufmann B, Koch K, Abshagen U
Int J Immunopharmacol. 1981;3(2):133-40. doi: 10.1016/0192-0561(81)90003-5.
The pharmacokinetics of 14C-activity were studied in male Sprague-Dawley rats over 24 and 288 h periods after oral i.v. administration respectively. After oral administration rapid and complete absorption of azimexone occurred. The elimination of radioactivity from plasma after i.v. administration could be best described by an open four-compartment-system yielding a terminal half-life of 74.45 h indicating the existence of deep compartment for azimexone or its metabolites. The renal clearance of 14C-activity decreased considerably after i.v. administration with progressing time. This points to an extensive metabolism of azimexone. Fifty-seven and sixty-seven per cent of the given 14C-activity could be recovered in urine within 24 h after i.v. and p.o. administration respectively and in both cases less than 1% of the doses in feces. Studies on the distribution of the labelled substance 24 h after i.v. administration showed highest concentration in gastric contents, spleen thyroid gland and bone marrow. Twelve days after i.v. administration the ratio of the 14C-content in organ/plasma was greatly increased for spleen, thymus, lung, bone marrow and thyroid gland as compared with the conditions 24 h after administration. Thus it can be assumed that the target organs for the immunomodulating activity of the drug belong to the deep compartment of azimexone or its metabolites.
分别在雄性Sprague-Dawley大鼠静脉注射和口服给药后24小时及288小时的时间段内研究了14C活性的药代动力学。口服给药后,阿齐美克迅速且完全吸收。静脉注射给药后,血浆中放射性的消除情况用开放的四室系统能得到最佳描述,其终末半衰期为74.45小时,这表明阿齐美克或其代谢产物存在深部隔室。静脉注射给药后,随着时间推移,14C活性的肾清除率显著降低。这表明阿齐美克存在广泛的代谢。静脉注射和口服给药后,分别在24小时内可在尿液中回收57%和67%给予的14C活性,两种情况下粪便中的剂量均不到1%。静脉注射给药后24小时对标记物质分布的研究表明,胃内容物、脾脏、甲状腺和骨髓中的浓度最高。静脉注射给药12天后,与给药后24小时的情况相比,脾脏、胸腺、肺、骨髓和甲状腺中器官/血浆的14C含量比值大幅增加。因此,可以假定该药物免疫调节活性的靶器官属于阿齐美克或其代谢产物的深部隔室。